S.Africa in $208 mln AIDS drug venture with Swiss Lonza
South Africa on Friday unveiled plans for a 1.6 billion rand ($208 million, 157 million euro) pharmaceutical plant, in a joint venture with Swiss biochemicals group Lonza to produce anti-AIDS drugs.
Feb 10, 2012
0
0